Get notified when ONCY files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: ONCY ONCOLYTICS BIOTECH INC 8-K

Oncolytics announces updates from REO 022 metastatic colorectal cancer study

Filed May 4, 2026 · Period ending May 4, 2026 · ~1 min read

Key Changes

  • medium

    Company disclosed updates from its REO 022 clinical trial evaluating treatment for metastatic colorectal cancer, though specific results were not detailed in the 8-K filing itself.

    Item 8.01 verify on EDGAR →
  • medium

    Updates were announced via press release dated May 4, 2026, attached as Exhibit 99.1 to the filing.

    Item 9.01 verify on EDGAR →

This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (FNGR 10-Q) is open in full — no account needed.

Partner

Trade ONCY commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov Press release (Ex 99.1) on EDGAR ↗

Source-verified from EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify